free sign up bonus real money casino

Cox Enterprises Nearing One-Third of its Ambitious Goal to Empower 34 Million People to Live More Prosperous Lives by 2034free sign up bonus real money casino 。

Wade Taylor IV helps No. 22 Texas A&M get by Texas TechBELLINGHAM, Wash., Dec. 05, 2024 (GLOBE NEWSWIRE) — , “the most agent-centric real estate brokerage on the planetTM” and the core subsidiary of eXp World Holdings, Inc. (Nasdaq: EXPI), proudly welcomes Joshua Smith, a Phoenix-based real estate icon, to its global network of agents. Smith is known for his record-setting achievements, which include 297 closings in 2023 and recognition as both a finalist in NAR’s “30 Under 30” and the Wall Street Journal’s 30 Top Realtor in the U.S. Smith brings with him a nearly 20-year legacy of excellence, a passion for mentorship and a vision to transform lives. He is shifting from a traditional team model to a coaching and collaboration-focused approach designed to empower agents to scale their businesses and create lasting impact. “eXp Realty is the perfect platform to take my mission global,” he said. “For too long, I’ve been a big fish in a small pond. With eXp, I can expand nationally and internationally, build my network and plug into a company where everyone wins. Together, we’ll revolutionize what’s possible in real estate.” Smith’s move is fueled by eXp Realty’s innovative model, robust tools and a culture of collaboration that mirrors his commitment to agent success. His personal goal to impact 40,000 agents and team leaders aligns seamlessly with eXp Realty’s focus on growth, innovation, and shared success. Leo Pareja, CEO of eXp Realty, met Joshua as part of the same 30 Under 30 class and is thrilled to have him join eXp. “Joshua’s vision, drive and passion for empowering agents embody everything eXp stands for,” said Pareja. “His ability to inspire others while achieving record-breaking success makes him a perfect fit for our global network. We’re thrilled to support him as he builds a legacy of growth, mentorship and innovation.” Over the years, Smith has mentored more than 5,000 agents and built a following through his popular GSD Mode Real Estate podcast, which has amassed over 31,000 subscribers and more than 5 million downloads. Joining eXp Realty allows him to amplify his impact through the company’s unmatched tools, training, and global reach. “I’ve known Leo Pareja for 13 years, and he’s the most brilliant person I’ve met in real estate,” Smith shared. “I’m excited to collaborate with incredible leaders like Leo and (eXp Realty leader) Mike Sherrard to create the best coaching and mentorship experience for agents and team leaders at eXp.” Smith’s expertise in residential real estate, agent development, and team scaling is now turbocharged by eXp’s global platform. His manager and eight-person team will also join eXp. “eXp isn’t just a brokerage – it’s a movement for growth, innovation, and shared success,” Smith said. “This is where the best come to grow, and I couldn’t be more excited to be part of it.” eXp World Holdings, Inc. (Nasdaq: EXPI) is the holding company for eXp Realty , FrameVR.io and SUCCESS Enterprises. eXp Realty is the largest independent real estate company in the world with more than 85,000 agents in the United States, Canada, the United Kingdom, Australia, France, India, Mexico, Portugal, South Africa, Puerto Rico, Brazil, Italy, Hong Kong, Colombia, Spain, Israel, Panama, Germany, the Dominican Republic, Greece, New Zealand, Chile, Poland and Dubai and continues to scale internationally. As a publicly traded company, eXp World Holdings provides real estate professionals the unique opportunity to earn equity awards for production goals and contributions to overall company growth. eXp World Holdings and its businesses offer a full suite of brokerage and real estate tech solutions, including an innovative residential and commercial brokerage model, professional services, collaborative tools and personal development. The cloud-based brokerage is powered by FrameVR.io technology, offering immersive 3D platforms that are deeply social and collaborative, enabling agents to be more connected and productive. SUCCESS Enterprises, anchored by SUCCESS magazine and its related media properties, was established in 1897 and is a leading personal and professional development brand and publication. For more information, visit https://expworldholdings.com. The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These statements include, but are not limited to, expectations related to future agent growth and attraction. Such forward-looking statements speak only as of the date hereof, and the Company undertakes no obligation to revise or update them. Such statements are not guarantees of future performance. Important factors that may cause actual results to differ materially and adversely from those expressed in forward-looking statements include the Company’s ability to attract new agents and other risks detailed from time to time in the Company’s Securities and Exchange Commission filings, including but not limited to the most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K eXp World Holdings, Inc. Denise Garcia, Managing Partner Hayflower Partners A photo accompanying this announcement is available atThe Boston Fleet allowed two goals in the final two minutes to fall 3-1 to the Toronto Sceptres to kick off the second Professional Women’s Hockey League’s season Saturday afternoon at Coca-Cola Coliseum in Toronto. The Fleet played for the inaugural PWHL title last season, falling in the final game to Minnesota. In the 2024-25 season opener, the Fleet were outshot 41-19, including 32-7 over the final two periods. Former Northeastern University goaltender Aerin Frankel was superb in stopping 38 of 40 shots. Hannah Miller scored a power-play goal with 1:38 left for the game-winner. Emma Maltais scored into an open net with 12 seconds left to account for the final. Boston took a 1-0 lead at 3:00 of the opening period thanks to a goal by captain Hilary Knight. Megan Keller and Hannah Bilka earned assists.

As Solana and Ethereum show little movement in their prices, the cryptocurrency spotlight shifts to Kaspa and XYZVerse, both gearing up for a market shift expected in January. XYZVerse, a promising player in the crypto scene, is anticipated to redefine the market with its innovative concept combining sports fandom, meme coin culture, and strong ecosystem development. Billing itself as the first all-sports meme token, XYZVerse is drawing the attention of sports fans and crypto enthusiasts. Its roadmap promises entertainment-focused dApps and growth driven by community input. Currently in the eighth stage of its presale, XYZ is priced at $0.001333, with expectations to reach $0.1 by the end of its presale, marking a significant increase from its initial price of $0.0001. XYZVerse aims to merge sports hype, meme culture, and blockchain technology to become an adaptable ecosystem, preparing for listings on centralized and decentralized exchanges, and offering rewards to contributors. With its unique appeal, community focus, and growth potential, XYZVerse is a notable contender to watch as January approaches. Meanwhile, Solana has experienced a 20.60% decline over the last month, trading currently between $177.72 and $201.47. Its technical indicators suggest it’s nearing an oversold condition. Ethereum has also seen a decrease, with a 2.42% drop this week, trading between $3232.83 and $3542.12, and potentially entering a consolidation phase. Kaspa has faced a 6.70% price reduction over the past week and is currently trading between $0.10 and $0.13, also indicating possible oversold conditions.The All Progressives Congress in Rivers State has elected Chief Tony Okocha as its new chairman. This was just as the new opposition party chairman declared that the party would take over the seat of power in the state come 2027. Okocha, the hitherto Caretaker Committee Chairman of the party in the state, was elected unopposed alongside other executives during the party’s state delegate congress held in Port Harcourt, the state capital, on Saturday. The delegate congress which was conducted through voice vote was presided over by Dr Adoye Omalez, who represented the party’s national chairman, Abdullahi Ganduje. Speaking after the exercise, the APC National Vice Chairman, South-South, Chief Victor Giadom, commended the party delegates for the peaceful manner they conducted themselves during the state delegate congress. Giadom stated that the peaceful conduct of the state delegate congress demonstrated the fact that APC in Rivers state is one united and indivisible party, even as he called party members to support the new executive of the party in order to move the party forward. In his acceptance speech, the newly elected Rivers State APC Chairman, Chief Tony Okocha, said that his election has gone a long way to prove all those who said the APC is not united and cannot conduct a peaceful election wrong. He lauded President Bola Tinubu for his numerous achievements in office so far, especially the resumption of production of petroleum products at the Port Harcourt Refinery, pointing out that the party will do more to pave the way to win all the elections in Rivers State. “If you know me very well, I’m an emotional person. Our joy is that our members came on their own volition. Nobody cajoled anybody to come, nobody bamboozled anybody to come here for the state primary election. “They came to show their love for the All Progressives Congress. I like to reassure you I’m sure you are seeing the indices and the variables already. Related News Wike's loyalist, Okocha, eyes Rivers APC chairmanship seat Fubara is Wike's political investment, says Tony Okocha Rivers APC condemns explosion at party secretariat “Those who said APC cannot conduct elections lied. APC will conduct and win elections and be in charge of government in Rivers State. Our business with you supporting us is to ensure that we route out a rudderless government in Rivers State. “By the year 2027 God keeping us alive, we will have an election in Rivers State and our target with you is to help us so that APC takes the reign of governance in Rivers State”, Okocha stated. Okocha added that with the mandate given to him and other elected executive officials, the party is set to capture the state in 2027. “From Assembly, local government areas, National Assembly, governorship election APC will win in Rivers state and also ensure that we return the hero of our time, President Bola Tinubu. Let me again use this opportunity to say to Nigerians that we are on cause. The APC is on cause in Nigeria I’m sure you have watched or you have heard what happened at the Port Harcourt Refinery some days ago? This is the tip of the iceberg that you will begin to see. “We have told you many times that Rome was not built in a day. That the day you plant a seed is not the day you will harvest it. So in less than two years we have started up and running. The President has also directed that the Kaduna and Warri refineries should be on the same speed as the Port Harcourt Refinery. So when we can achieve this I’m sure the problems of Nigeria will be half solved. “So let me say it to all of us, particularly my colleagues here, it’s one family. I want to assure you of the appreciation of APC in Rivers State that we will come up with the best for the interest of all of us. I want to thank the delegation from the National who have come here and dutifully and profoundly led this process to this right. “Let me on behalf of the party thank you for your courage, dexterity for the love you have for the party. For this reason, you have left all that you are doing to come to Port Harcourt to superintendent this election to its logical conclusion. We would not have succeeded in concluding this process if INEC had not come to preside over this election. Of course, it’s their responsibility to preside over party primary elections. The leader of the delegation is no other person than the leader of INEC in the state he came here himself. Other elected positions during the state delegates congress were that of the Deputy Chairman of the party, the State Secretary, the Publicity Secretary, the State Auditor, the State women leader, the Youth leader, the legal advisor and Zonal leaders of the party in the three senatorial districts of the State. Our correspondent reports that the state delegate congress was supervised by the state resident electoral Commissioner, Dr Joseph Alalibo.

, /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended . "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. R&D expenses were for the full year ended , compared to for the full year ended . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in , which were associated with the complete response letter remediation. G&A expenses were for the full year ended , compared to for the full year ended . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. For the full year ended , stock-based compensation expense was as compared to for the prior year. The primary reason for the increase was due to the amounts being realized over 12 months in the year ended , as compared to three months post-plan adoption in the year ended . Net loss was , or per share for the year ended , compared to a net loss of , or per share for the year ended . The increase in net loss was primarily due to the increase in our operating expenses. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at , including in Citius Oncology's Annual Report on Form 10-K for the year ended , filed with the SEC on , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. 908-967-6677 x113 STiR-communications -- Financial Tables Follow –History Suggests This Defense Stock Will Outperform the Defense MarketThomas Frank unhappy with officials in game with BrightonClinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated Leonard Mazur , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Liquidity As of September 30, 2024 , the Company had $3.3 million in cash and cash equivalents. As of September 30, 2024 , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November 25, 2024 . During the year ended September 30, 2024 , the Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations. Research and Development (R&D) Expenses R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5 million during the year ended September 30, 2024 , compared to $2.0 million for the year ended September 30, 2023 , as the plan was initiated in July 2023 . For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382 , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss Net loss was $39.4 million , or ($5.97) per share for the year ended September 30, 2024 , compared to a net loss of $32.5 million , or ($5.57) per share for the year ended September 30, 2023 , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024 , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 3,251,880 $ 26,480,928 Inventory 8,268,766 — Prepaid expenses 2,700,000 7,889,506 Total Current Assets 14,220,646 34,370,434 Property and equipment, net — 1,432 Operating lease right-of-use asset, net 246,247 454,426 Other Assets: Deposits 38,062 38,062 In-process research and development 92,800,000 59,400,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 68,784,858 Total Assets $ 116,651,751 $ 103,611,150 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 4,927,211 $ 2,927,334 License payable 28,400,000 — Accrued expenses 17,027 476,300 Accrued compensation 2,229,018 2,156,983 Operating lease liability 241,547 218,380 Total Current Liabilities 35,814,803 5,778,997 Deferred tax liability 6,713,800 6,137,800 Operating lease liability – non current 21,318 262,865 Total Liabilities 42,549,921 12,179,662 Commitments and Contingencies Stockholders' Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354 Additional paid-in capital 271,440,421 253,056,133 Accumulated deficit (201,370,218) (162,231,379) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 70,077,450 90,831,108 Non-controlling interest 4,024,380 600,380 Total Equity 74,101,830 91,431,488 Total Liabilities and Equity $ 116,651,751 $ 103,611,150 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 11,906,601 14,819,729 General and administrative 18,249,402 15,295,584 Stock-based compensation – general and administrative 11,839,678 6,616,705 Total Operating Expenses 41,995,681 36,732,018 Operating Loss (41,995,681) (36,732,018) Other Income: Interest income, net 758,000 1,179,417 Gain on sale of New Jersey net operating losses 2,387,842 3,585,689 Total Other Income Net 3,145,842 4,765,106 Loss before Income Taxes (38,849,839) (31,966,912) Income tax expense 576,000 576,000 Net Loss (39,425,839) (32,542,912) Net loss attributable to non-controlling interest 287,000 - Deemed dividend on warrant extension (1,047,312) (1,151,208) Net Loss Applicable to Common Stockholders $ (40,186,151) (33,694,120) Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted $ (5.97) (5.57) Weighted Average Common Shares Outstanding

As another frigid winter settles over Minnesota, with temperatures dipping into the teens, people like Ed Kranz are embracing the cold—and working up quite a sweat. Kranz and his wife, Colleen, are among the Minnesotans who believe the best way to endure winter is to heat up in saunas, then cool off in their state's icy weather. On a bone-chilling Sunday morning, they set up a mobile wood-fired sauna from their business, Saunable, near a frozen lake in the Minneapolis suburb of Eagan. After about 10 minutes of sweating in the 185-degree-Fahrenheit sauna, they moseyed outside into the 15-degree temps, lingering around a fire in bathing suits before repeating the process three or four more times. One brave soul dipped into a hole in the frozen lake for a post-sauna cold plunge. Their hot-and-cold venture is common in Minnesota, where plenty of residents embrace sauna culture for warmth and community, per the . Devotees say they're mingling Old World traditions with newfangled internet-based communities, and making social connections in a society that can feel isolating. More .

Chennai: Barricades and umbrellas were swept away by gusty winds and road users scurried for cover as rains poured, with cyclone Fengal inching closer to the shoreline on Saturday, leaving many areas in and around Chennai under water. Curiously, a lot of people, especially young men and women, frolicked at beaches, and strangely, visitors could be spotted at the Mamallapuram world heritage site too, despite the government warning people against going near beaches, in view of the high tides. Wind speed was pretty high in coastline areas such as Marakkanam in Villupuram district. Rainwater entered the premises of two state-run hospitals at Chromepet, a general hospital and a facility for thoracic medicine, both of which are located side by side and frequented by people. Water was close to the level of one’s ankle even inside the hospital, leaving health care seekers and doctors in a tight spot. Police and local authorities placed sandbags at entry points and said all steps were being taken to address the issue. Barricades could be seen strewn around at several roads including Anna Salai and a traffic light fell down at Sriperumbudur. Several residential neighbourhoods were heavily inundated here. These included parts of Korattur, Velachery-Madipakkam and Kodungaiyur. Rain water entered houses in suburban localities, such as the Hasthinapuram–Tirumalai Nagar, and residents had to place even refrigerators and washing machines on cots to prevent them from getting damaged. In a rain-related incident, a migrant worker who tried to withdraw cash from an ATM here, was reportedly electrocuted. Public transportation services were hit and people used flyovers and spaces beneath them as parking lots to avoid a repeat of what was endured during the 2015 floods. In view of the rains and copious inflows, reservoirs such as Chembarambakkam looked like an ocean. Greater Chennai Corporation (GCC) authorities said 22,000 personnel including engineers, officials and sanitary workers were on the job and a total of 1,686 motor pumps of various capacities including 25-hp and 100-hp were in use. As many as 484 tractor-mounted heavy-duty pumps and 137 pumps of 100-hp capacity have been deployed. The GCC said work was on in a ‘war-footing’ to clear waterlogging in 134 spots and out of the 9 trees that fell, 5 have been cleared.

Kogi has potential to put Nigeria on global tourism mapHUNTSVILLE, Texas (AP) — Jonah Pierce had 20 points in Presbyterian's 67-42 win against Youngstown State on Friday night. Pierce added nine rebounds for the Blue Hose (4-3). Kory Mincy scored 12 points, shooting 5 for 11, including 2 for 5 from beyond the arc. Kobe Stewart had 11 points and finished 4 of 9 from the field. The Penguins (2-3) were led by Ty Harper, who posted 12 points. EJ Farmer added 10 points and three steals for Youngstown State. Nico Galette also had five points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .